TENOSYNOVIAL GIANT CELL TUMOR
Clinical trials for TENOSYNOVIAL GIANT CELL TUMOR explained in plain language.
Never miss a new study
Get alerted when new TENOSYNOVIAL GIANT CELL TUMOR trials appear
Sign up with your email to follow new studies for TENOSYNOVIAL GIANT CELL TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise for rare joint tumor in early trial
Disease control Recruiting nowThis phase 2 trial tests a daily oral drug called pimicotinib in 20 Japanese adults with tenosynovial giant cell tumor (TGCT) that cannot be removed by surgery. The study aims to see if the drug is safe, how it moves through the body, and whether it shrinks tumors. Participants t…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE2 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill for tough tumors enters human testing
Disease control Recruiting nowThis early-stage study tests an experimental pill called ABSK021 in people with advanced solid tumors (including a rare joint tumor called TGCT) who have run out of standard options. The main goal is to check safety and find the best dose, while also seeing if the drug can shrink…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE1 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Glow-in-the-Dark dye may help surgeons spot hidden tumor cells
Diagnosis Recruiting nowThis study tests whether a dye called indocyanine green (ICG) can help surgeons see tenosynovial giant cell tumors (TGCT) during surgery. About 40 people with TGCT will get an ICG injection before their operation. The dye makes tumor tissue glow under a special camera, which surg…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE4 • Sponsor: Shanghai Jiao Tong University Affiliated Sixth People's Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:08 UTC
-
New study tracks how TGCT patients fare on vimseltinib in everyday life
Knowledge-focused Recruiting nowThis observational study follows 100 people with tenosynovial giant cell tumor (TGCT) who are taking vimseltinib as part of their routine care. Researchers will collect data on how long patients stay on the drug and how it affects their quality of life. The study does not change …
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Liver risk under microscope: TURALIO study seeks answers
Knowledge-focused Recruiting nowThis study follows up to 30 adults with tenosynovial giant cell tumor (TGCT) who had liver test abnormalities while taking TURALIO. The goal is to track long-term liver failure risk and understand how the drug may cause liver injury. Participants will be monitored after stopping …
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Sponsor: Daiichi Sankyo • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC